Multiple Sclerosis, Rituximab, Hypogammaglobu...

In part two of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about the latest developments in BTK inhibitors for MS, including safety signals, trial results, and future directions. For more information, please read about the abstract that was presented at t ...  Show more

In part one of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about recent multiple sclerosis clinical trial data. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting. Read more about the Fenebrutinib Trial. ...  Show more

Dr. Shuvro Roy and Dr. Annette Langer-Gould discuss the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to prevent infection risks. Show reference: https://www.neurology.org/doi/10.1212/NXI.0 ...  Show more

Drs. Justin Abbatemarco and Géraldine Androdias discuss the impact of immune checkpoint inhibitors on the course of multiple sclerosis.  Show reference:  https://www.neurology.org/doi/10.1212/NXI.0000000000200202   This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for ...  Show more

Dr. Justin Abbatemarco and Dr. Aaron Zelikovich discuss the safety and efficacy of satralizumab and its role in the current treatment landscape for myasthenia gravis. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00514-3/fulltext 

We get to the bottom of a medical mystery – what causes multiple sclerosis? A series of studies have compellingly pointed the finger at the virus behind glandular fever. We see if they stack up and assess what it means for the future of preventing and treating MS. Then nearly two ...  Show more